Table 1.
Safety N = 8 | Pharmacodynamic N = 16 | Overall N = 24 | |
---|---|---|---|
Age (years) | |||
Median (range) | 57 (28–72) | 70 (38–82) | 65 (28–82) |
Number of patients | |||
Male | 5 (62.5%) | 11 (69%) | 16 (67%) |
Female | 3 (37.5%) | 5 (31%) | 8 (33%) |
Primary disease site | |||
Prostate | 1 (12.5%) | 5 (31%) | 6 (25%) |
Colorectal | 1 (12.5%) | 3 (19%) | 4 (17%) |
Urothelial | 0 (0%) | 2 (13%) | 2 (8%) |
Ovarian | 1 (12.5%) | 1 (6%) | 2 (8%) |
Lung | 1 (12.5%) | 1 (6%) | 2 (8%) |
Other | 4 (50%) | 4 (25%) | 8 (34%) |
Number of organs with metastases | |||
1 | 2 (25%) | 5 (31%) | 7 (29%) |
2 | 3 (37.5%) | 5 (31%) | 8 (34%) |
3+ | 3 (37.5%) | 6 (38%) | 9 (37%) |